From Evidence to Health-System Implementation: The Evolution of Procalcitonin-Guided Antimicrobial Therapy Through Bibliometric Mapping

In hospitals around the world, doctors face a difficult daily choice. When a patient arrives with a fever, a cough, or signs of a serious infection, the safest immediate action is often to start antibiotics. These drugs are powerful tools that save lives by killing bacteria. However, they are not harmless. Using them when they are not needed, or using them for too long, can cause side effects for the patient and, on a larger scale, helps bacteria learn how to survive the drugs, making future infections harder to treat. For decades, the medical community has searched for a way to know exactly when to start these medicines and, more importantly, when to stop them. One promising tool that has emerged is a substance in the blood called procalcitonin. Think of it as a biological signal flare: when the body is fighting a bacterial infection, this signal rises high; when the threat is viral or non-bacterial, it stays low. By measuring this signal, doctors hope to make smarter decisions about antibiotics, giving them only when truly necessary and stopping them as soon as the danger passes.

A recent study by researchers Mohammad Awawdeh and Ilyas Awawdeh looked at the entire history of research on this idea to see how far the medical world has actually come. They did not test the drug themselves; instead, they acted as cartographers, mapping out thousands of scientific papers published between 2000 and 2025 to understand the shape of the field. They gathered 512 studies that specifically looked at using procalcitonin to guide antibiotic decisions. Their goal was to see if the science had moved from simple testing in a lab to real, routine use in hospitals. The picture they found was one of great scientific success but a significant struggle in the real world. The researchers discovered that while scientists have produced a massive amount of evidence proving that this method works in controlled settings, very few of those studies have successfully shown how to make it a permanent part of hospital care across many different locations.

The story of this research field is one of rapid growth. In the early 2000s, only a handful of papers were written each year about using procalcitonin to manage antibiotics. But starting around 2012, the number of studies began to climb steadily, reaching a peak in 2019 and remaining high through 2025. This surge of activity was driven largely by researchers in North America and Western Europe, with the United States, Switzerland, and the United Kingdom leading the way. The most common places to see this research were in the treatment of sepsis, a life-threatening reaction to infection, and in intensive care units where patients are critically ill. The researchers found that the most influential work came from major medical journals, with the top ten most-read studies being large, carefully designed experiments that compared patients treated with procalcitonin guidance against those treated with standard care. These landmark studies helped prove that using the blood test could safely reduce the number of days patients spent on antibiotics.

However, the researchers noticed a sharp divide between what the studies proved and how they were done. They sorted the 512 papers into two categories: how strong the scientific evidence was, and how far the idea had moved toward being a standard part of hospital routine. On the strength side, the field is robust. About 22 percent of the studies were high-quality randomized trials or summaries of many trials, which are considered the gold standard of medical proof. The rest were observational studies or smaller experiments. But when the researchers looked at the implementation side, the numbers told a different story. Nearly half of all the studies, 237 of them, were purely theoretical or descriptive; they discussed the idea or tested it in a way that did not involve actually putting it into practice in a hospital. Another 137 studies were pilots, meaning they were small tests to see if the idea was possible, or they were focused on designing the rules for how to use the test.

The most striking finding was the scarcity of large-scale, real-world success. Only 121 studies showed that the method had been tried at a single hospital. Even more telling, just 15 studies demonstrated that the method worked across multiple hospitals, and a mere two studies showed that it had been successfully integrated into a healthcare system and sustained over time. This means that while the scientific community has spent decades proving that procalcitonin can guide antibiotic use effectively, very little of that work has shown how to make it stick in the messy, complex reality of different hospitals. The research suggests that the challenge is no longer about proving the science works, but about figuring out how to make it work everywhere, every day, without needing constant supervision or special support.

The map of this research also revealed where the knowledge is concentrated. The strongest networks of collaboration were between countries in North America and Europe, particularly between the United States and Switzerland. These regions have the resources, the laboratory infrastructure, and the specialized teams needed to run these tests and manage the data. The study noted that this concentration raises a question about whether these methods can be used in other parts of the world where hospitals might not have the same access to rapid blood testing or the same level of specialist support. The researchers observed that the field is expanding into new areas, such as treating children and newborns, but the evidence for these groups is still developing. The core of the research remains focused on adults with severe infections, where the stakes are highest and the need for precise antibiotic use is most urgent.

Ultimately, this analysis paints a clear picture of a field at a crossroads. The science is mature; we know the tool works. The evidence is substantial, with thousands of citations and hundreds of studies confirming that using procalcitonin can reduce unnecessary antibiotic use. Yet, the journey from a successful experiment to a standard hospital practice is far from complete. The researchers conclude that the next step for the medical community is not to run more small tests, but to focus on large, practical studies that show how to embed this method into the daily workflow of diverse healthcare systems. The goal is to move beyond proving that the idea is good, to showing how it can be done reliably, sustainably, and equitably for patients everywhere, regardless of where they receive their care.